Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Monica Ramchandani

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
American Journal of Pharmaceutical Education|May 13, 2017
A Framework for Integrating Biosimilars Into the Didactic Core Requirements of a Doctor of Pharmacy CurriculumEdward Li, Jennifer Liu, Monica Ramchandani
Immunotherapy|August 4, 2018
Scientific and statistical considerations in evaluating the analytical similarity of ABP 501 to adalimumabRenuka Sivendran, José Ramírez, Monica Ramchandani, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 26, 2017
Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare CommunityRichard Markus, Jennifer Liu, Monica Ramchandani, et al.
P & T : a Peer-Reviewed Journal for Formulary Management|February 16, 2019
Biosimilars: Considerations for PayersJames Smeeding, Daniel C Malone, Monica Ramchandani, et al.
Regulatory Toxicology and Pharmacology : RTP|March 4, 2021
Use of nonclinical toxicity studies to support biosimilar antibody developmentLauren Mihalcik, Vincent Chow, Monica Ramchandani, et al.
Advances in Therapy|June 12, 2019
A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501Richard Markus, Helen J McBride, Monica Ramchandani, et al.
Advances in Therapy|November 10, 2021
A Review of the Totality of Evidence for the Development and Approval of ABP 710 (AVSOLA), an Infliximab BiosimilarWalter Reinisch, Stanley Cohen, Monica Ramchandani, et al.
Infectious Diseases and Therapy|April 19, 2023
Consistent Effects of Early Remdesivir on Symptoms and Disease Progression Across At-Risk Outpatient Subgroups: Treatment Effect Heterogeneity in PINETREE StudySamuel M Brown, Morgan J Katz, Adit A Ginde, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
American Journal of Pharmaceutical Education|May 13, 2017
A Framework for Integrating Biosimilars Into the Didactic Core Requirements of a Doctor of Pharmacy CurriculumEdward Li, Jennifer Liu, Monica Ramchandani
Immunotherapy|August 4, 2018
Scientific and statistical considerations in evaluating the analytical similarity of ABP 501 to adalimumabRenuka Sivendran, José Ramírez, Monica Ramchandani, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 26, 2017
Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare CommunityRichard Markus, Jennifer Liu, Monica Ramchandani, et al.
P & T : a Peer-Reviewed Journal for Formulary Management|February 16, 2019
Biosimilars: Considerations for PayersJames Smeeding, Daniel C Malone, Monica Ramchandani, et al.
Regulatory Toxicology and Pharmacology : RTP|March 4, 2021
Use of nonclinical toxicity studies to support biosimilar antibody developmentLauren Mihalcik, Vincent Chow, Monica Ramchandani, et al.
Advances in Therapy|June 12, 2019
A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501Richard Markus, Helen J McBride, Monica Ramchandani, et al.
Advances in Therapy|November 10, 2021
A Review of the Totality of Evidence for the Development and Approval of ABP 710 (AVSOLA), an Infliximab BiosimilarWalter Reinisch, Stanley Cohen, Monica Ramchandani, et al.
Infectious Diseases and Therapy|April 19, 2023
Consistent Effects of Early Remdesivir on Symptoms and Disease Progression Across At-Risk Outpatient Subgroups: Treatment Effect Heterogeneity in PINETREE StudySamuel M Brown, Morgan J Katz, Adit A Ginde, et al.
Pageof 1